Antonio Maria Borzì1, Giovanni Condorelli2, Antonio Biondi3, Francesco Basile4, Enzo Saretto Dante Vicari5, Carola Buscemi6, Salvatore Luca7, Marco Vacante8. 1. Department of Clinical and Experimental Medicine, Specialization School in Geriatrics, University of Catania, AOU Policlinico, Catania, Italy. Electronic address: antoniomaria.borzi@gmail.com. 2. Department of Clinical and Experimental Medicine, Specialization School in Geriatrics, University of Catania, AOU Policlinico, Catania, Italy. Electronic address: giocondor81@gmail.com. 3. Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy. Electronic address: abiondi@unict.it. 4. Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy. Electronic address: fbasile@unict.it. 5. Department of Clinical and Experimental Medicine, Specialization School in Geriatrics, University of Catania, AOU Policlinico, Catania, Italy. Electronic address: enzodante@email.it. 6. Department of Clinical and Experimental Medicine, Specialization School in Geriatrics, University of Catania, AOU Policlinico, Catania, Italy. Electronic address: carola.buscemi@gmail.com. 7. Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy. Electronic address: salvatoreluca@virgilio.it. 8. Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy. Electronic address: marcovacante@yahoo.it.
Abstract
INTRODUCTION: There is an unclear association between type 2 diabetes and mild cognitive impairment in the elderly. Both diseases are more prevalent in the older adults compared to the younger counterpart. Some anti-diabetic drugs seem to influence positively the evolution of mild cognitive impairment. This retrospective study investigated the effect of vildagliptin, an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), on the cognitive functioning of elderly diabetic patients with mild cognitive impairment (MCI) documented at mini mental state examination (MMSE). METHODS: We included 60 diabetic elderly people which were divided in 2 groups: Group A, 30 patients with HbA1c (glycated hemoglobin) ≤7.5% and treated with metformin, and Group B, 30 patients with HbA1c >7.5%, and treated with metformin plus vildagliptin. We collected data on MMSE, fasting plasma glucose (FPG) and HbA1c at baseline and after 180 ± 10 days from the beginning of treatment. RESULTS: The two groups exhibited significantly different values in FPG (P < 0.05) and HbA1c (P < 0.01) at baseline, and in MMSE score (P < 0.001) after treatment. The intragroup comparison showed a significant (P < 0.05) reduction in MMSE score in group A, and in HbA1c (P = 0.01) in group B. CONCLUSION: Vildagliptin in addition to metformin resulted in the maintenance of MMSE score, showing a protecting role on cognitive functioning compared to the metformin only group.
INTRODUCTION: There is an unclear association between type 2 diabetes and mild cognitive impairment in the elderly. Both diseases are more prevalent in the older adults compared to the younger counterpart. Some anti-diabetic drugs seem to influence positively the evolution of mild cognitive impairment. This retrospective study investigated the effect of vildagliptin, an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), on the cognitive functioning of elderly diabeticpatients with mild cognitive impairment (MCI) documented at mini mental state examination (MMSE). METHODS: We included 60 diabetic elderly people which were divided in 2 groups: Group A, 30 patients with HbA1c (glycated hemoglobin) ≤7.5% and treated with metformin, and Group B, 30 patients with HbA1c >7.5%, and treated with metformin plus vildagliptin. We collected data on MMSE, fasting plasma glucose (FPG) and HbA1c at baseline and after 180 ± 10 days from the beginning of treatment. RESULTS: The two groups exhibited significantly different values in FPG (P < 0.05) and HbA1c (P < 0.01) at baseline, and in MMSE score (P < 0.001) after treatment. The intragroup comparison showed a significant (P < 0.05) reduction in MMSE score in group A, and in HbA1c (P = 0.01) in group B. CONCLUSION:Vildagliptin in addition to metformin resulted in the maintenance of MMSE score, showing a protecting role on cognitive functioning compared to the metformin only group.
Authors: Juraj Secnik; Hong Xu; Emilia Schwertner; Niklas Hammar; Michael Alvarsson; Bengt Winblad; Maria Eriksdotter; Sara Garcia-Ptacek; Dorota Religa Journal: Alzheimers Res Ther Date: 2021-12-02 Impact factor: 6.982
Authors: Che-Yuan Wu; Michael Ouk; Yuen Yan Wong; Natasha Z Anita; Jodi D Edwards; Pearl Yang; Baiju R Shah; Nathan Herrmann; Krista L Lanctôt; Moira K Kapral; Bradley J MacIntosh; Jennifer S Rabin; Sandra E Black; Walter Swardfager Journal: Alzheimers Dement Date: 2020-08-16 Impact factor: 16.655